Business Context and Reporting Period
Company: Sharps Technology, Inc. (Note: Input metadata referenced "Skyai, Inc.", but the filing text identifies the registrant as Sharps Technology, Inc., trading as STSS).
Reporting Period: Quarterly period ended September 30, 2024 (Form 10-Q).
Business Overview: Sharps is a pre-revenue medical device company focused on designing, patenting, and commercializing safety syringes. The company operates a manufacturing facility in Hungary and maintains a corporate office in Melville, New York. As of the reporting date, the company has not generated significant revenue from product sales.
Capital Structure Update: Effective October 16, 2024, the company completed a 1-for-22 reverse stock split. All share and per-share data in this filing have been retroactively adjusted.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,685,060) | $(2,022,344) | $(4,769,774) | $(6,739,999) |
| Loss Per Share (Basic/Diluted) | $(1.27) | $(3.77) | $(4.53) | $(13.01) |
| Cash and Cash Equivalents | $2,473,197 (as of Sept 30, 2024) | |||
| Working Capital | $67,820 (as of Sept 30, 2024) | |||
| Total Debt (Notes Payable) | $2,334,142 (as of Sept 30, 2024) | |||
| Warrant Liability | $1,027,102 (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 15% in Q3 2024 ($2.02M) compared to Q3 2023 ($2.36M). Research and Development (R&D) expenses dropped 35% due to a strategic shift from R&D to manufacturing activities. General and Administrative (G&A) expenses decreased 12%.
- Net Loss Reduction: The net loss for Q3 2024 decreased by 16% compared to the prior year period, primarily driven by reduced operating costs and a significant non-cash gain from the fair value adjustment of warrant liabilities ($416,560 gain in Q3 2024 vs. $321,981 in Q3 2023).
- Debt Financing: In September 2024, the company entered into a Senior Secured Note agreement with an aggregate principal of $4.375 million (including OID interest), maturing January 31, 2025. This resulted in a new Notes Payable balance of $2.33 million on the balance sheet.
- Inventory Build: Inventory increased to $2.02 million (up from $1.71 million at year-end 2023) as the company builds commercial quantities to fulfill future orders.
Outlook, Risks, and Contingencies
Going Concern Warning
Management has raised substantial doubt regarding the company's ability to continue as a going concern. With working capital of only $67,820, the company does not have sufficient funds to finance planned operations for the next 12 months. Continued operations depend on raising additional equity or debt financing.
Legal Proceedings
- Barry Berler Lawsuit: A co-founder and former CTO filed suit alleging unpaid consulting fees, bonuses, and severance disputes totaling approximately $456,000, plus a separate arbitration claim for $500,000 regarding royalty agreements. The company intends to defend vigorously.
- Plastomold Industries Lawsuit: A supplier filed a lawsuit claiming $1.762 million in damages for unpaid invoices and alleged breach of contract regarding defective machinery. The company has filed counterclaims alleging the machinery failed to meet specifications.
Business Developments
- Stericare Supply Agreement: Signed a 5-year agreement to sell 520 million units of Sologard syringes, with expected revenues exceeding $50 million. The agreement is targeted to commence in November 2024.
- Asset Purchase Agreement: A $1 million escrow deposit for a potential $35 million asset purchase from InjectEZ, LLC was forfeited in July 2024 as the transaction was not consummated by the deadline. Negotiations for an amendment are ongoing.
- Nasdaq Compliance: The company regained compliance with Nasdaq listing rules regarding minimum bid price on November 5, 2024, following the reverse stock split.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.47 million cash balance against the $4.375 million debt obligation maturing in January 2025 and the stated inability to fund operations for 12 months.
- Revenue Recognition: Confirm the timeline for the Stericare supply agreement (targeted Nov 2024) and the status of the first commercial sale (a small order to a South American distributor in June 2024).
- Legal Exposure: Assess the potential financial impact of the pending lawsuits (Berler and Plastomold) totaling over $2.7 million in claimed damages.
- Warrant Liability Volatility: Monitor the fair value adjustments of warrant liabilities, which significantly impacted net income/loss in the current period ($2.09M gain YTD 2024) and are subject to market price fluctuations.
- Asset Acquisition Status: Determine if the amended Asset Purchase Agreement with InjectEZ will close and if the company can secure the necessary financing to complete the $35M transaction.